Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 3

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828 · tracked via the Priya Life Science Spain tracker
Sponsor
Phase
Phase 3
Started
2025-09-10
Last updated
2026-10-15

Condition(s) studied

Severe Alopecia Areata

Investigational drug(s) / intervention(s)

Ritlecitinib higher dose →Ritlecitinib lower dose →

Ritlecitinib higher dose: Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

Ritlecitinib lower dose: Study intervention will be provided as oral capsules centrally by the sponsor in HDPE bottles.

Study summary

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.

This study is seeking participants who have:

* previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031).
* at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031).
* received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports.

All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial.

Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial.

The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home.

The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

Eligibility

Sex
ALL
Min age
6 Years
Max age
14 Years
Healthy volunteers
No
Inclusion Criteria: 1. Participants with alopecia areata (AA) (including alopecia totalis \[AT\] and alopecia universalis \[AU\]) who completed the studies B7981027 or B7981031. 2. For participants originating from Study B7981031: At least 50% scalp hair loss due to AA (ie, a SALT score of ≥50) at both the Screening and Baseline visits. Exclusion Criteria: 1. Exclusion criteria for participants originating from Study B7981027 with ≤ 30 Days between last dose in Study B7981027 and first visit of Study B7981028 1. During Study B7981027 or in the period between the last dose of study intervention in Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol. 2. Study participants discontinued from Study B7981027 due to issues other than safety-related events and considered by the investigator for enrolment in Study B7981028 must have resolution of the issue(s) resulting in discontinuation from the parent study prior to enrolment in Study B7981028. 2. Exclusion criteria for participants originating from Study B7981031 or from Study B7981027 with \>30 Days between last dose in Study B7981027 and first visit of Study B7981028 1. During Study B7981031 or Study B7981027 or in the period between the last dose of study intervention in Study B7981031 or Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol. 2. Any present malignancies or history of malignancies or lymphoproliferative disorders. 3. Evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection, history (one or more episodes) of severe or serious cytomegalovirus (CMV), herpes zoster (shingles) or disseminated herpes simplex, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). \-

Primary outcome measure(s)

  • Incidence of treatment-emergent adverse events (AEs). — From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).
  • Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study. — From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

Trial sites (67)

FacilityCityRegionStatus
University of California~ Irvine Irvine California Recruiting
Southern California Clinical Research Santa Ana California Recruiting
Children's Hospital Colorado Aurora Colorado Recruiting
Children's National Hospital Washington D.C. District of Columbia Recruiting
Pediatric Skin Research Miami Florida Recruiting
Endeavor Health Clinical Operations Skokie Illinois Recruiting
Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana Recruiting
Kindred Hair and Skin Center Marriottsville Maryland Not Yet Recruiting
Michigan Dermatology Institute Waterford Michigan Recruiting
Ear, Nose & Throat Consultants, LLC Omaha Nebraska Recruiting
Skin Specialists, PC dba Schlessinger MD Omaha Nebraska Recruiting
University of New Mexico Health Sciences Center Albuquerque New Mexico Recruiting
University of New Mexico-IDS Pharmacy Albuquerque New Mexico Recruiting
Northwest Dermatology Institute Portland Oregon Recruiting
Penn State Health Milton S. Hershey Medical Center Hershey Pennsylvania Recruiting
Medical University of South Carolina - South Carolina Translational Research Nexus Clinic Charleston South Carolina Recruiting
Dell Children's Medical Center Austin Texas Not Yet Recruiting
Driscoll Children's Hospital Corpus Christi Texas Recruiting
3A Research El Paso Texas Recruiting
Austin Institute for Clinical Research Pflugerville Texas Recruiting
Texas Dermatology and Laser Specialists San Antonio Texas Recruiting
Children's Wisconsin Milwaukee Wisconsin Not Yet Recruiting
Medical College of Wisconsin Milwaukee Wisconsin Not Yet Recruiting
China-Japan Friendship Hospital Beijing Beijing Municipality Recruiting
Beijing Children's hospital, Capital Medical University Beijing Beijing Municipality Recruiting
Beijing Tongren Hospital affiliated to Capital Medical University Beijing Beijing Municipality Recruiting
Beijing Tongren Hospital affiliated to Capital Medical University Beijing Beijing Municipality Recruiting
The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong Recruiting
Hunan Children's Hospital Changsha Hunan Recruiting
Huashan Hospital, Fudan University Shanghai Shanghai Municipality Recruiting
Chengdu Women and Children Center Hospital Chengdu Sichuan Recruiting
The First People's Hospital of Hangzhou Hangzhou Zhejiang Recruiting
Hangzhou Third Hospital Hangzhou Zhejiang Recruiting
Fakultní Nemocnice Brno Brno Czechia Not Yet Recruiting
Fakultni Nemocnice Plzen Pilsen Czechia Recruiting
Prof. MUDr. Petr Arenberger, DrSc., MBA Prague Czechia Not Yet Recruiting
Fakultni nemocnice Bulovka Praha 8 - Libeň Czechia Recruiting
Hospices Civils de Lyon - CIC - Hopital Louis Pradel Bron France Recruiting
Hospices Civils de Lyon - Hopital Femme Mere Enfant Bron France Recruiting
CHU de Dijon Bourgogne Dijon France Recruiting

+ 27 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07029828 on ClinicalTrials.gov ↗ ← All trials in Spain